How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,005 results for

Androgenic Alopecia

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Full Text available with Trip Pro

Clinical efficacy of a cosmetic treatment by Crescina(®) human follicle stem cell on healthy males with androgenetic alopecia. Androgenetic alopecia (AGA) is the most common cause of hair loss among males, characterized by progressive thinning of the scalp hairs and defined by various patterns. The main factors underling hair loss in AGA are genetic predisposition and increased sensitivity of the hair follicles to androgens, leading to a shortening of the anagen phase. In the present study (...) , the authors investigated the efficacy of a commercially available cosmetic lotion, Crescina(®) HFSC (human follicle stem cell; Labo Cosprophar AG, Basel, Switzerland), in promoting hair growth and in decreasing hair loss.A placebo-controlled, randomized trial was carried out on healthy males suffering from alopecia grade II to IV. Anagen rate and hair resistance to traction (pull test) were assessed after 2 and 4 months of treatment using phototricogram and pull test technique.Crescina(®) HFSC applied

2013 Dermatology and therapy Controlled trial quality: uncertain

162. Plasma Rich in Growth Factors (PRGF-Endoret)in the Treatment of Androgenetic Alopecia

25, 2013 Last Update Posted : June 25, 2013 Sponsor: Biotechnology Institute IMASD Information provided by (Responsible Party): Biotechnology Institute IMASD Study Details Study Description Go to Brief Summary: Androgenetic alopecia (AGA) or common baldness is the most common cause of hair loss in both men and women and is caused by the action of androgens in genetically predisposed individuals. This clinical trial was designed to evaluate the efficacy and safety of using a preparation (...) inflammation or infection in the intervention area Presence of active systemic infections. Background of cancerous or precancerous lesions. Background of connective or rheumatic diseases. Suffering from any serious blood disorders. To have undergone treatments for alopecia in the previous 6 months. Previous hair implants Intake of drugs that affect hair loss. Be undergoing immunosuppressive therapy and/or anticoagulants. Known intolerance to mesotherapy. Taking contraceptives containing cyproterone acetate

2013 Clinical Trials

163. A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia

a global photograph from an earlier assessment (i.e., a withdrawal visit), then that photograph was assessed during the panel review. Number of Participants With the Indicated Change From Baseline (BL) in the Stage of Androgenic Alopecia (AGA) According to the Norwood-Hamilton Scale at 26 Weeks and 52 Weeks [ Time Frame: Baseline, Week 26 and Week 52 ] The investigator/designee assessed the stage (Stage I to Stage VII) of AGA (i.e., male pattern baldness [MPB]) by utilizing the Norwood-Hamilton scale (...) , used to measure the progression of MPB. Stage VII indicates worse balding than Stage I. Assessment was made by direct visual examination (aided by pictures) of the participant at Screening (Baseline), Week 26, and Week 52. "v," vertex; most of the hair loss (commonly seen with advancing age) is on the vertex. "a," type a variant; major features are (1) the entire anterior hairline border recedes in unison; (2) there is no simultaneous balding of the vertex. The number of participants with stage

2013 Clinical Trials

164. Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia

National University Yangsan Hospital Study Details Study Description Go to Brief Summary: Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile dysfunction, the latter causes scaling, itching of the scalp. Recently, Pulpkin Seed Oil shows some improved clinical efficacy on scalp hair growth in men with androgenetic alopecia (...) Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Effect

2013 Clinical Trials

165. Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia

: GlaxoSmithKline Information provided by (Responsible Party): GlaxoSmithKline ( Stiefel, a GSK Company ) Study Details Study Description Go to Brief Summary: Treatment of male pattern hair loss (MPHL) or androgenetic alopecia (AGA) with 5α-reductase inhibitor (5-ARIs) has been associated with sexual dysfunction including erectile dysfunction and loss of libido. This will be a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the impact of dutasteride treatment on sexual (...) consent, or compliance with study procedures.Note: the investigator may consult with the GSK medical monitor if a condition could interfere with the subject's safety. Global scalp hair thinning, including occipital areas. Scarring of the scalp, including prior hair transplant or scalp reduction, or any other condition or disease of the scalp or hair, including diseases of the hair shaft (e.g., tinea infection, non-androgenetic-cause of alopecia, psoriatic dermatitis or other psoriatic lesions

2013 Clinical Trials

166. Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. Full Text available with Trip Pro

Androgenetic Alopecia: Identification of Four Genetic Risk Loci and Evidence for the Contribution of WNT Signaling to Its Etiology. The pathogenesis of androgenetic alopecia (AGA, male-pattern baldness) is driven by androgens, and genetic predisposition is the major prerequisite. Candidate gene and genome-wide association studies have reported that single-nucleotide polymorphisms (SNPs) at eight different genomic loci are associated with AGA development. However, a significant fraction (...) descent to confirm the association with AGA at these loci. Combined analysis of the replication and the meta-analysis data identified four genome-wide significant risk loci for AGA on chromosomes 2q35, 3q25.1, 5q33.3, and 12p12.1. The strongest association signal was obtained for rs7349332 (P=3.55 × 10(-15)) on chr2q35, which is located intronically in WNT10A. Expression studies in human hair follicle tissue suggest that WNT10A has a functional role in AGA etiology. Thus, our study provides genetic

2013 Journal of Investigative Dermatology

167. Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. (Abstract)

Health status, coping strategies, and alexithymia in subjects with androgenetic alopecia: a questionnaire study. Androgenic alopecia (AGA) is viewed as a relatively mild dermatologic condition; however, affected individuals feel that alopecia is a serious condition with major consequences in their life.The objective of this study was to assess the health status, the risk of anxiety/depression, the coping strategies, and alexithymia in subjects with AGA.Consecutive subjects referred (...) their alopecia than to the objective clinical rating. Avoidant coping strategies were selected more frequently by AGA subjects if they were GHQ-12 positive and had alexithymia. To have alexithymia modified all coping strategies in AGA female subjects but not in AGA male subjects. Physicians should be aware that the impact of AGA is not limited to symptoms, and should help people to deal with their emotional responses to alopecia, such as anger and worry, and their beliefs about the consequences

2013 American journal of clinical dermatology

168. Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients

Alopecia (female pattern hair loss) Exclusion Criteria: patients with alopecia areata or cicatricial alopecia pregnancy and breastfeeding have undergone any specific treatment in the last 06 months use of drugs with anti-androgenic properties patients with signs or symptoms of hyper-androgynism Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information provided (...) diagnosed with female pattern hair loss will undergo mesotherapy sessions weekly for ten weeks. One group will receive 0.5%/2ml minoxidil application and a control group will receive application of placebo (saline 0.9%). Biopsy of the scalp, trichogram and trichoscopy (Fotofinder) will be performed before and 08 weeks after treatment as a method objective evaluation of the response Condition or disease Intervention/treatment Phase Female Pattern Alopecia Drug: Minoxidil Drug: Saline Phase 3 Detailed

2012 Clinical Trials

169. The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. (Abstract)

(p = 0.048), and lack of exercise (p = 0.012) were associated with increased vertex hair loss. Higher testosterone levels were associated with increased temporal and vertex hair loss patterns (p < 0.039). Increased stress, increased smoking, having more children, and having a history of hypertension and cancer were all associated with increased hair thinning (p < 0.05).This study implicates several environmental risk factors in the pathophysiology of female alopecia. (...) The contribution of endogenous and exogenous factors to female alopecia: a study of identical twins. In this study, the authors investigated the potential contribution of environmental factors and testosterone levels on androgenic alopecia in women.Ninety-eight identical female twins were recruited from 2009 to 2011. Subjects were asked to complete a comprehensive questionnaire, provide a sputum sample for testosterone analysis, and pose for standardized digital photography. Frontal, temporal

2012 Plastic and reconstructive surgery

170. Age dependent associations between androgenetic alopecia and prostate cancer risk. Full Text available with Trip Pro

Age dependent associations between androgenetic alopecia and prostate cancer risk. Both prostate cancer and androgenetic alopecia are strongly age-related conditions that are considered to be androgen dependent, but studies of the relationship between them have yielded inconsistent results. We aimed to assess whether androgenetic alopecia at ages 20 and 40 years are associated with risk of prostate cancer.At a follow-up of the Melbourne Collaborative Cohort Study, men were asked to assess (...) their hair pattern at ages 20 and 40 years relative to eight categories in showcards. Cases were men notified to the Victorian Cancer Registry with prostate cancer diagnosed between cohort enrollment (1990-1994) and follow-up attendance (2003-2009). Flexible parametric survival models were used to estimate age-varying HRs and predicted cumulative probabilities of prostate cancer by androgenetic alopecia categories.Of 9,448 men that attended follow-up and provided data on androgenetic alopecia, we

2012 Cancer Epidemiology & Biomarkers and Prevention

171. This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer.

This is a Phase 1, Open-label, and Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Efficacy of TAK-385 in Japanese Patients With Androgen Deprivation Treatment-naïve Nonmetastatic Prostate Cancer. A Study of TAK-385 in Hormone Treatment-naïve Participants With Prostate Cancer - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail (...) antiandrogen, non-steroidal androgen) for prostate cancer. Participants who have not undergone surgical castration. Participants with serum testosterone at screening greater than (>) 150 nanogram per deciliter (ng/dL). Participants meeting either of the following criteria for prostate-specific antigen (PSA) at screening. Untreated prostate cancer: PSA at screening > 4.0 nanogram per milliliter (ng/mL) Treated* prostate cancer: PSA at screening > 0.2 ng/mL. Participants who have undergone prostatectomy

2014 Clinical Trials

172. Topical Bimatoprost Effect on Androgen Dependent Hair Follicles

Responsible Party: Duke University ClinicalTrials.gov Identifier: Other Study ID Numbers: Pro00017573 First Posted: June 23, 2014 Results First Posted: August 20, 2014 Last Update Posted: September 5, 2014 Last Verified: July 2014 Keywords provided by Duke University: male pattern hair loss androgenetic alopecia bimatoprost Additional relevant MeSH terms: Layout table for MeSH terms Alopecia Alopecia Areata Hypotrichosis Hair Diseases Skin Diseases Pathological Conditions, Anatomical Androgens Bimatoprost (...) . Thirty-three subjects were consented and screened, 9 entered and 9 completed the study. Condition or disease Intervention/treatment Phase Male Pattern Hair Loss Androgenetic Alopecia Drug: Bimatoprost Drug: Placebo Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 33 participants Allocation: Randomized Intervention Model: Crossover Assignment Masking: Triple (Participant, Investigator, Outcomes Assessor) Primary Purpose

2014 Clinical Trials

173. Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors

. If a patient declines to participate in voluntary exploratory research and/or genetic component of study, there will be no penalty or loss of benefit to the patient and he/she will not be excluded from other aspects of the study. Part A Dose Escalation Patients must have histological or cytological confirmation of a solid tumour of either locally advanced or metastatic castrate resistant prostate cancer (mCRPC), breast, bladder, ovarian, gastric or salivary duct carcinoma where an Androgen Receptor pathway (...) Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor Tumors - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study

2014 Clinical Trials

174. Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique Full Text available with Trip Pro

Obliteration of Alopecia by Hair-Lifting: A New Concept and Technique A new concept and technique of treatment of male-pattern alopecia are described. The concept is to remove, in serial stages, segments of skin that measure about 3 cm by 7 to 10 cm from the bald area of an alopecic scalp, and to raise the remaining hairy portion into the previously bald area.The technique consists of undermining the skin in the normal plane of cleavage between the galea and the sub-aponeurotic loose connective (...) for tonsure baldness in men and even in the skull-cap type of androgenic alopecia in women.

1977 Journal of the National Medical Association

175. New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp Full Text available with Trip Pro

New Treatment for Seborrheic Alopecia: The Ligature of the Arteries of the Scalp Bilateral ligature of the superficial temporal arteries and of the posterior auricular arteries is proposed as a treatment for seborrheic alopecia. The arterial circulatory dynamics are, thus, replaced by capillary circulatory dynamics. Hypoxia is produced which inhibits enzymatic systems and lessens nocuous action of androgen and lipid factors on the pilosebaceous effectors. The histologic study shows (...) that the production of sebum is greatly reduced and the condition of the hair follicle is strikingly improved.

1977 Journal of the National Medical Association

176. Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Full Text available with Trip Pro

Hair loss in women: medical and cosmetic approaches to increase scalp hair fullness. Androgenetic alopecia affects both men and women. In men it produces male pattern hair loss with bitemporal recession and vertex baldness. In women it produces female pattern hair loss (FPHL) with diffuse alopecia over the mid-frontal scalp. FPHL occurs as a result of nonuniform hair follicle miniaturization within follicular units. Diffuse alopecia is produced by a reduction in the number of terminal fibres (...) per follicular unit. Baldness occurs only when all hairs within the follicular units are miniaturized and is a relatively late event in women. The concepts of follicular units and primary and secondary hair follicles within follicular units are well established in comparative mammalian studies, particularly in sheep. However, discovery of these structures in the human scalp hair and investigation of the changes in follicular unit anatomy during the development of androgenetic alopecia have

2011 British Journal of Dermatology

177. Androgen Excess (Treatment)

occur. [ ] Women using these methods can be reassured that these methods do not exacerbate hair growth, but they will not lower the androgen levels if they are elevated. Combining one of these local measures with systemic treatment might help achieve rapid response and better patient satisfaction. Next: Surgical Care Surgical removal is the standard therapy for ovarian and adrenal tumors that result in androgen excess. Surgery for PCOS is less commonly performed today, since adhesions routinely (...) tumors should be evaluated and treated by an obstetrician-gynecologist or a gynecologic oncologist. Previous Next: Diet In women who are obese, a modification of life style and weight loss are pivotal. Suppression of hair growth is unlikely without weight loss. [ ] A loss of 5-10% of body weight for obese women with PCOS in a 6-month period is enough to greatly improve hirsutism in most women. [ ] Previous Next: Activity Regular exercise and behavioral modification programs are essential for acute

2014 eMedicine.com

178. Androgen Excess (Overview)

vesicles, and the prostate. Postnatal females are not as sensitive as the fetus to androgens, which induce the growth of sexual hair, temporal balding, acne, clitoral growth, sebum production, and a deepening of the voice. Oral androgens decrease high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol. With androgen excess, the extent of these changes is dependent on the level of androgens in the blood. Androgen effects on various tissues and systems Androgens (...) antiandrogens; on the other hand, administration of testosterone in women with hypoactive sexual desire disorder results in improvements in libido and sexual function. [ , ] Bone Androgens have important roles in bone mineralization either directly or through aromatization to estrogen. Lower androgen concentrations have been associated with bone loss in various age groups. [ ] Breast Androgen receptors are present in mammary epithelial cells in addition to estrogen and progesterone receptors. The proposed

2014 eMedicine.com

179. Androgen Excess (Follow-up)

Metab . 1961 Nov. 21:1440-7. . Cela E, Robertson C, Rush K, Kousta E, White DM, Wilson H, et al. Prevalence of polycystic ovaries in women with androgenic alopecia. Eur J Endocrinol . 2003 Nov. 149(5):439-42. . Kahana M, Grossman E, Feinstein A, Ronnen M, Cohen M, Millet MS. Skin tags: a cutaneous marker for diabetes mellitus. Acta Derm Venereol . 1987. 67(2):175-7. . Franks S. Polycystic ovary syndrome. N Engl J Med . 1995 Sep 28. 333(13):853-61. . Azziz R, Carmina E, Dewailly D, Diamanti (...) Androgen Excess (Follow-up) Androgen Excess Follow-up: Further Outpatient Care, Prognosis Edition: No Results No Results Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. https://profreg.medscape.com/px/getpracticeprofile.do?method=getProfessionalProfile&urlCache=aHR0cHM6Ly9lbWVkaWNpbmUubWVkc2NhcGUuY29tL2FydGljbGUvMjczMTUzLWZvbGxvd3Vw processing > Androgen Excess Follow-up Updated: Mar 14

2014 eMedicine.com

180. Androgen Excess (Diagnosis)

vesicles, and the prostate. Postnatal females are not as sensitive as the fetus to androgens, which induce the growth of sexual hair, temporal balding, acne, clitoral growth, sebum production, and a deepening of the voice. Oral androgens decrease high-density lipoprotein (HDL) cholesterol and increase low-density lipoprotein (LDL) cholesterol. With androgen excess, the extent of these changes is dependent on the level of androgens in the blood. Androgen effects on various tissues and systems Androgens (...) antiandrogens; on the other hand, administration of testosterone in women with hypoactive sexual desire disorder results in improvements in libido and sexual function. [ , ] Bone Androgens have important roles in bone mineralization either directly or through aromatization to estrogen. Lower androgen concentrations have been associated with bone loss in various age groups. [ ] Breast Androgen receptors are present in mammary epithelial cells in addition to estrogen and progesterone receptors. The proposed

2014 eMedicine.com

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>